T1	Procedure 15 27	chemotherapy
T2	Condition 32 35	MBC
R1	causal Arg1:T1 Arg2:T2	
T3	Observation 0 7	History
T4	Value 53 63	< 6 months
T5	Procedure 87 109	cytotoxic chemotherapy
T6	Qualifier 117 129;142 149	neo-adjuvant setting
T7	Qualifier 133 149	adjuvant setting
T8	Condition 168 188	metastatic diagnosis
T9	Drug 191 202	Trastuzumab
T10	Temporal 203 235	≤ 21 days prior to randomization
T11	Reference_point 222 235	randomization
R2	multi Arg1:T10 Arg2:T11	
R3	Has_temporal Arg1:T9 Arg2:T10	
T12	Procedure 238 253	Hormone therapy
T13	Temporal 254 285	< 7 days prior to randomization
T14	Reference_point 272 285	randomization
R4	Has_index Arg1:T13 Arg2:T14	
T15	Condition 296 317	peripheral neuropathy
T16	Qualifier 321 330	Grade ≥ 3
T17	Measurement 321 326	Grade
T18	Value 327 330	≥ 3
R5	Has_value Arg1:T17 Arg2:T18	
R6	multi Arg1:T16 Arg2:T17	
R7	Has_qualifier Arg1:T15 Arg2:T16	
T19	Temporal 288 295	Current
R8	Has_temporal Arg1:T15 Arg2:T19	
T20	Temporal 361 384	within the last 5 years
T21	Condition 419 450	carcinoma in situ of the cervix
T22	Qualifier 397 418	appropriately treated
T23	Procedure 411 418	treated
R9	multi Arg1:T22 Arg2:T23	
R10	Has_qualifier Arg1:T21 Arg2:T22	
T24	Condition 452 479	non-melanoma skin carcinoma
T25	Condition 489 503	uterine cancer
T26	Measurement 481 486	Stage
T27	Value 487 488	I
R11	Has_value Arg1:T26 Arg2:T27	
R12	AND Arg1:T25 Arg2:T26	
T28	Condition 350 360	malignancy
T29	Qualifier 344 349	other
R13	Has_qualifier Arg1:T28 Arg2:T29	
R14	Has_temporal Arg1:T28 Arg2:T20	
T30	Negation 386 396	except for
*	OR T21 T24 T25
T31	Non-representable 505 574	or other cancers with a similar outcome as those previously mentioned
T32	Scope 397 503	appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer
R15	Has_negation Arg1:T32 Arg2:T30	
T33	Procedure 586 598	radiotherapy
T34	Temporal 577 585	Previous
R16	Has_temporal Arg1:T33 Arg2:T34	
T35	Condition 665 678	breast cancer
T36	Qualifier 654 664	metastatic
T37	Qualifier 634 650	locally advanced
T38	Qualifier 620 632	unresectable
*	OR T36 T37 T38
T39	Scope 620 664	unresectable, locally advanced or metastatic
R17	Has_scope Arg1:T35 Arg2:T39	
T40	Value 697 710	more than 25%
T41	Measurement 714 733;743 753	marrow-bearing bone irradiated
R18	Has_value Arg1:T41 Arg2:T40	
T42	Non-representable 577 865	Previous radiotherapy for the treatment of unresectable, locally advanced or metastatic breast cancer is not allowed if more than 25% of marrow-bearing bone has been irradiated or the last fraction of radiotherapy has been administered within approximately 3 weeks prior to randomization.
T43	Condition 867 883	Brain metastases
T44	Qualifier 893 902	untreated
T45	Qualifier 904 915	symptomatic
T46	Qualifier 920 935	require therapy
T47	Procedure 963 972	radiation
T48	Procedure 974 981	surgery
T49	Procedure 986 1019	other therapy to control symptoms
*	OR T49 T48 T47
T50	Condition 1025 1041	brain metastases
T51	Temporal 1042 1080	within 2 months prior to randomization
T52	Reference_point 1067 1080	randomization
R19	multi Arg1:T51 Arg2:T52	
R20	Has_temporal Arg1:T50 Arg2:T51	
T53	Scope 963 1019	radiation, surgery, or other therapy to control symptoms
R21	causal Arg1:T53 Arg2:T50	
*	OR T45 T46 T44
T54	Scope 893 935	untreated, symptomatic, or require therapy
R22	Has_scope Arg1:T43 Arg2:T54	
*	OR T43 T53
T55	Drug 1140 1154	anthracyclines
T56	Drug 1156 1167	Doxorubicin
T57	Drug 1171 1192	liposomal doxorubicin
T58	Multiplier 1193 1205	> 500 mg/m^2
T59	Drug 1207 1217	epirubicin
T60	Multiplier 1218 1230	> 900 mg/m^2
T61	Drug 1232 1244	mitoxantrone
T62	Multiplier 1245 1256	> 120mg/m^2
T63	Drug 1261 1271	idarubicin
T64	Multiplier 1272 1283	> 90 mg/m^2
R23	Has_multiplier Arg1:T63 Arg2:T64	
R24	Has_multiplier Arg1:T61 Arg2:T62	
R25	Has_multiplier Arg1:T59 Arg2:T60	
*	OR T56 T57
T65	Scope 1156 1192	Doxorubicin or liposomal doxorubicin
R26	Has_multiplier Arg1:T65 Arg2:T58	
T66	Scope 1156 1283	Doxorubicin or liposomal doxorubicin > 500 mg/m^2; epirubicin > 900 mg/m^2; mitoxantrone > 120mg/m^2 and idarubicin > 90 mg/m^2
T67	Scope 1094 1154	exposure to the following cumulative doses of anthracyclines
R27	Subsumes Arg1:T67 Arg2:T66	
T68	Condition 1294 1309	unstable angina
T69	Temporal 1286 1293	Current
R28	Has_temporal Arg1:T68 Arg2:T69	
T70	Condition 1335 1359	congestive heart failure
T71	Qualifier 1323 1334	symptomatic
R29	Has_qualifier Arg1:T70 Arg2:T71	
T72	Condition 1364 1386	ventricular arrhythmia
T73	Qualifier 1387 1406	requiring treatment
T74	Procedure 1397 1406	treatment
R30	multi Arg1:T73 Arg2:T74	
R31	Has_qualifier Arg1:T72 Arg2:T73	
*	OR T72 T70
T75	Condition 1420 1441	myocardial infarction
T76	Temporal 1442 1480	within 6 months prior to randomization
T77	Reference_point 1467 1480	randomization
R32	Has_index Arg1:T76 Arg2:T77	
R33	Has_temporal Arg1:T75 Arg2:T76	
T78	Measurement 1483 1524	Left ventricular ejection fraction (LVEF)
T79	Value 1525 1534	below 50%
R34	Has_value Arg1:T78 Arg2:T79	
T80	Temporal 1535 1586	within approximately 28 days prior to randomization
T81	Reference_point 1573 1586	randomization
R35	Has_index Arg1:T80 Arg2:T81	
R36	Has_temporal Arg1:T78 Arg2:T80	
T82	Condition 1630 1660	congestive heart failure (CHF)
T83	Qualifier 1618 1629	symptomatic
R37	Has_qualifier Arg1:T82 Arg2:T83	
T84	Measurement 1610 1614	LVEF
T85	Value 1600 1609	decreased
R38	Has_value Arg1:T84 Arg2:T85	
T86	Drug 1684 1695	trastuzumab
T87	Qualifier 1675 1683	adjuvant
T88	Temporal 1666 1674	previous
R39	Has_qualifier Arg1:T86 Arg2:T87	
R40	Has_temporal Arg1:T86 Arg2:T88	
T89	Scope 1618 1705	symptomatic congestive heart failure (CHF) with previous adjuvant trastuzumab treatment
*	OR T84 T89
T90	Observation 1589 1596	History
R41	Has_temporal Arg1:T84 Arg2:T90	
R42	Has_temporal Arg1:T89 Arg2:T90	
T91	Measurement 1708 1726	Cardiac troponin I
T92	Value 1727 1738	≥ 0.2 ng/mL
R43	Has_value Arg1:T91 Arg2:T92	
T93	Temporal 1739 1770	within 28 days of randomization
T94	Reference_point 1757 1770	randomization
R44	Has_index Arg1:T93 Arg2:T94	
R45	Has_temporal Arg1:T91 Arg2:T93	
T95	Condition 1780 1787	dyspnea
T96	Qualifier 1773 1779	Severe
R46	Has_qualifier Arg1:T95 Arg2:T96	
T97	Condition 1824 1843	advanced malignancy
T98	Procedure 1865 1890	continuous oxygen therapy
T99	Temporal 1857 1864	current
R47	Has_temporal Arg1:T98 Arg2:T99	
T100	Condition 1807 1820	complications
R48	causal Arg1:T100 Arg2:T97	
T101	Qualifier 1847 1890	requiring current continuous oxygen therapy
R49	multi Arg1:T101 Arg2:T98	
*	OR T100 T101
T102	Scope 1807 1890	complications of advanced malignancy or requiring current continuous oxygen therapy
R50	causal Arg1:T95 Arg2:T102	
T107	Condition 2285 2294	lactation
T108	Condition 2272 2281	pregnancy
T109	Temporal 2264 2271	Current
*	OR T107 T108
T110	Scope 2272 2294	pregnancy or lactation
R51	Has_temporal Arg1:T110 Arg2:T109	
T113	Condition 2431 2465	human immunodeficiency virus (HIV)
T114	Temporal 2402 2409	Current
R52	Has_temporal Arg1:T113 Arg2:T114	
T115	Condition 2474 2485;2505 2510	hepatitis B virus
T116	Condition 2493 2510	hepatitis C virus
*	OR T115 T116 T113
T117	Condition 2524 2535	intolerance
T118	Condition 2557 2574	infusion reaction
T119	Measurement 2547 2552	Grade
T120	Value 2553 2556	3-4
R53	Has_value Arg1:T119 Arg2:T120	
R54	AND Arg1:T118 Arg2:T119	
T121	Condition 2579 2595	hypersensitivity
T122	Drug 2599 2610	trastuzumab
T123	Drug 2612 2627	murine proteins
T124	Drug 2632 2641	docetaxel
*	OR T123 T124 T122
T125	Scope 2599 2641	trastuzumab, murine proteins, or docetaxel
R55	Has_scope Arg1:T121 Arg2:T125	
T103	Qualifier 1901 1907	severe
T104	Qualifier 1909 1921	uncontrolled
T105	Condition 1922 1938	systemic disease
T106	Qualifier 1944 1966	clinically significant
T129	Condition 1983 1992;2007 2014	pulmonary disease
T130	Condition 1997 2014	metabolic disease
T128	Condition 1967 1981;2007 2014	cardiovascular disease
T131	Condition 2016 2039	wound healing disorders
T132	Condition 2041 2047	ulcers
T133	Condition 2052 2066	bone fractures
*	OR T132 T133 T131 T134
*	OR T129 T128 T130
T134	Scope 1967 2014	cardiovascular, pulmonary, or metabolic disease
R56	Has_qualifier Arg1:T134 Arg2:T106	
T135	Scope 1944 2066	clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures
R57	Has_qualifier Arg1:T105 Arg2:T104	
R58	Has_qualifier Arg1:T105 Arg2:T103	
R59	AND Arg1:T135 Arg2:T105	
T111	Procedure 2322 2347	investigational treatment
T112	Temporal 2348 2399	within approximately 28 days prior to randomization
R60	Has_temporal Arg1:T111 Arg2:T112	
T136	Reference_point 2386 2399	randomization
R61	Has_index Arg1:T112 Arg2:T136	
T126	Condition 2650 2666	hypersensitivity
T137	Drug 2681 2692	study drugs
T138	Drug 2727 2761	drugs formulated in polysorbate 80
*	OR T137 T138
T139	Scope 2681 2761	study drugs, including the excipients, or any drugs formulated in polysorbate 80
R62	Has_scope Arg1:T126 Arg2:T139	
T127	Observation 2809 2866	unwilling to comply with the requirements of the protocol
T140	Observation 2799 2805;2819 2866	unable to comply with the requirements of the protocol
*	OR T140 T127
T141	Qualifier 2070 2075	Major
T142	Procedure 2076 2094	surgical procedure
T143	Qualifier 2098 2109	significant
T144	Condition 2110 2126	traumatic injury
R63	Has_qualifier Arg1:T144 Arg2:T143	
R64	Has_qualifier Arg1:T142 Arg2:T141	
*	OR T144 T142
T145	Temporal 2127 2178	within approximately 28 days prior to randomization
T146	Reference_point 2165 2178	randomization
R65	Has_index Arg1:T145 Arg2:T146	
T147	Scope 2070 2126	Major surgical procedure or significant traumatic injury
R66	Has_temporal Arg1:T147 Arg2:T145	
T148	Mood 2182 2206	anticipation of the need
T149	Procedure 2211 2224	major surgery
R67	Has_mood Arg1:T149 Arg2:T148	
T150	Temporal 2225 2261	during the course of study treatment
T151	Reference_point 2246 2261	study treatment
R68	Has_index Arg1:T150 Arg2:T151	
T152	Procedure 2252 2261	treatment
R69	multi Arg1:T151 Arg2:T152	
R70	Has_temporal Arg1:T149 Arg2:T150	
*	OR T149 T147
T153	Observation 2297 2307	History of
R71	Has_temporal Arg1:T111 Arg2:T153	
T154	Observation 2513 2523	History of
T155	Scope 2547 2574	Grade 3-4 infusion reaction
R73	Subsumes Arg1:T117 Arg2:T155	
*	OR T117 T121
T156	Scope 2524 2641	intolerance (including Grade 3-4 infusion reaction) or hypersensitivity to trastuzumab, murine proteins, or docetaxel
R72	Has_temporal Arg1:T156 Arg2:T154	
